NEOADJUVANT PUBLICATIONS & ABSTRACTS

Neoadjuvant data


Evidence / Neoadjuvant

MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

Source: San Antonio Breast Cancer Symposium® 2024 Authors: Joyce O’Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigators’ Group Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Read More

Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers

Publication: Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1553. Authors: Alejandro Rios-Hoyo, Kaitlyn Xiong, Jiawei Dai, Christina Yau, Michal Marczyk, Rolando Garcia-Milian, Denise M Wolf, Laura A Huppert, Rita Nanda, Gillian L Hirst, Erin F Cobain, Laura J van 't Veer, Laura J Esserman, Lajos Pusztai Title: Hormone Receptor Read More